Vor Biopharma
Stock Forecast, Prediction & Price Target
Vor Biopharma Financial Estimates
Vor Biopharma Revenue Estimates
Vor Biopharma EBITDA Estimates
Vor Biopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $1.42M Low: $1.42M High: $1.42M avg. 0% | Avg: $10M Low: $10M High: $10M avg. 600.00% | Avg: $40.90M Low: $40.90M High: $40.90M avg. 309.03% | Avg: $123.59M Low: $123.59M High: $123.59M avg. 202.15% |
Net Income
% change YoY
| $-68.78M N/A | $-90.77M -31.97% | $-117.86M -29.84% | Avg: $-114.46M Low: $-120.94M High: $-52.40M avg. 2.88% | Avg: $-123.46M Low: $-104.14M High: $-51.06M avg. -7.86% | Avg: $-63.16M Low: $-63.16M High: $-63.16M avg. 48.84% | Avg: $-34.49M Low: $-34.49M High: $-34.49M avg. 45.39% |
EBITDA
% change YoY
| $-67.58M N/A | $-90.89M -34.48% | $-114.37M -25.83% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.85 N/A | -$2.29 -23.78% | -$1.75 23.58% | Avg: -$1.4 Low: -$1.8 High: -$0.78 avg. 20.24% | Avg: -$1.27 Low: -$1.55 High: -$0.76 avg. 9.29% | Avg: -$0.94 Low: -$0.94 High: -$0.94 avg. 25.75% | Avg: -$0.51 Low: -$0.51 High: -$0.51 avg. 45.39% |
Operating Expenses
% change YoY
| $69.01M N/A | $93.41M 35.35% | $126.03M 34.91% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Vor Biopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 22.31% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -120.94M, average is -114.46M and high is -52.40M.
What is Vor Biopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 277.79% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $1.42M, average is $1.42M and high is $1.42M.
What is Vor Biopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 25.16% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$1.8, average is -$1.4 and high is $-0.78.
What is the best performing analyst?
In the last twelve months analysts have been covering Vor Biopharma stock. The most successful analyst is David Nierengarten.